Keʻena Honua

20 ʻAukake 2025, ua hoʻolaha ʻo Abbisko Therapeutics ua ʻae ke Center for Drug Evaluation (CDE) o ka China National Medical Products Administration (NlPA) i ka noi lND no ka mea hoʻopaʻa PD-1 waha noiʻi a Abbisko, ABSK043, i hui pū ʻia me Shanghai Alist Pharmaceuticals KRAS ...E heluhelu hou aku»

I kēia mau lā iho nei, ua loaʻa i ka haʻawina Antengene's Phase I/II CLINCH o ATG-022 (CLDN18.2 antibody-drug conjugate), he maʻi ʻelemakule me ka maʻi ʻaʻai gastric holomua i holomua ma nā laina he nui o ka chemotherapy, immunotherapy a me ka therapy i kuhikuhi ʻia ʻoiai nā metastases ākea i loaʻa kahi pane piha (CR) foll...E heluhelu hou aku»

Ma ʻAukake 13, 2025, ua hoʻokuʻu ka Pacific Time, ka pūnaewele kūhelu o ka 2025 World Conference on Lung Cancer (WCLC) i nā ʻōlelo noiʻi i koho ʻia no ka ʻaha kūkā o kēia makahiki, ʻO kekahi o nā mea koʻikoʻi ka ʻōlelo hōʻuluʻulu manaʻo no ka hoʻokolohua lapaʻau mua o ka Phase 1 o HLX43, ʻo Henlius' PD-L1 ADC. He...E heluhelu hou aku»

Ma ʻAukake 7, ua hoʻolaha ke Kikowaena no ka Loiloi Lāʻau Lapaʻau (CDE) o ka National Medical Products Administration (NMPA) ua hāpai ʻia ka inikini PA3-17 no ka hoʻokomo ʻia ʻana i loko o ka hoʻolālā lapaʻau holomua, i manaʻo ʻia no ka mālama ʻana i nā poʻe maʻi makua me ka relapsed/refractory T-cell acute lymph...E heluhelu hou aku»

Ma ʻAukake 11, ua hōʻike ke Center for Drug Evaluation (CDE) o ka National Medical Products Administration (NMPA) ua hāpai ʻia ka noi a InxMed no nā papa IN10018 no ka hoʻolālā ʻana i ka breakthrough therapy, i manaʻo ʻia no ka hui pū ʻana me D-1553 e mālama i ka KRA holomua kūloko a metastatic paha...E heluhelu hou aku»

He maʻi ʻo Mr. X i kona mau makahiki he 40 i ʻike ʻia me ka acral melanoma. Ma hope o ke ʻoki kino radical ma hope o kona ʻike ʻia ʻana i ka makahiki 2015, ua kūpaʻa kona kūlana no ʻeiwa mau makahiki. ʻO ka mea pōʻino, ma kahi o hoʻokahi makahiki i hala aku nei, ua hoʻi hou kāna maʻi me nā metastases i nā māmā ʻelua. ʻOiai ua loaʻa iā ia ka inguinal a me ka pelvic l...E heluhelu hou aku»

Ma Iulai 31, ua hoʻolaha pū ʻo AstraZeneca lāua ʻo Merck & Co. ua ʻae ʻia kā lākou mea hoʻopaʻa PARP ʻo Lynparza, i hui pū ʻia me Abiraterone a me prednisolone, ma Kina no ka mālama ʻana i nā poʻe maʻi makua me ka maʻi kanesa prostate metastatic castration-resistant (mCRPC) nāna e lawe i ka germline a i ʻole kekahi...E heluhelu hou aku»

Ma Iulai 31, 2025, hoʻolaha ʻo ImmuneOnco Biopharmaceuticals i ka ʻikepili palekana mua a me ka pono mai ka Phase 2 open-label, multicenter study o IMM2510 i hui pū ʻia me ka chemotherapy no nā poʻe maʻi laina mua me ka maʻi ʻaʻai māmā ʻaʻole liʻiliʻi (NSCLC) holomua i mālama ʻia ma Kina. Ma Iulai 1, 2025,...E heluhelu hou aku»

Ma Iulai 30, ua ʻāpono kūhelu ka National Medical Products Administration (NMPA) i ke kūʻai aku ʻana o HICARA no ka mālama ʻana i nā poʻe maʻi makua me ka relapsed a refractory paha i ka nui o ka lymphoma B-cell (r/r LBCL) i loaʻa i ʻelua a ʻoi aku paha nā laina o ka systemic therapy. Hoʻokomo pū kēia me ka diffuse large B-cell ...E heluhelu hou aku»

I kēia mau lā aku nei, ua loaʻa i kahi mea maʻi me ke kanesa pancreatic holomua i hāʻule i nā laina lapaʻau he nui ma mua ka emi ʻana o ka puʻupuʻu ma hope o ka loaʻa ʻana o ka lāʻau lapaʻau KD-496 CAR-T cell, me ka hoʻomaha hōʻoia i mālama ʻia ma 180 mau lā ma hope o ka mālama ʻana. I kēia manawa, nui nā hoʻokolohua lapaʻau o kahi mea hou...E heluhelu hou aku»

Ma Iulai 16, ua paʻi ka puke pai honua kiʻekiʻe ʻo Nature Medicine i ka ʻikepili noiʻi ma SHR-A1904, kahi antibody-drug conjugate (ADC) e kuhikuhi ana iā claudin 18.2 (CLDN18.2), no ka mālama ʻana i ka maʻi ʻaʻai gastric holomua a i ʻole ka maʻi ʻaʻai gastroesophageal junction (GC/GEJC). Ua hana nā mea noiʻi i kahi hana mua-i-...E heluhelu hou aku»

Iulai 17, 2025 - Ua hoʻolaha ʻo Innovent Biologics ua paʻi ʻo Nature Medicine i nā hopena o ke aʻo ʻana o ka Phase 1 o IBI343, kahi anti-CLDN18.2 ADC hou, no ka mālama ʻana i ka adenocarcinoma gastric/gastroesophageal junction (G/GEJ) holomua. Hoʻolaha ʻia ma kēia alakaʻi honua ...E heluhelu hou aku»